

Rev05
 Update: Aug,11,2025

DATASHEET


VEGF R2/KDR hFc Chimera, Human

Cat. No.: Z03965


Product Introduction

Species	Human
Protein Construction	<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> VEGF R2/KDR (Ala20-Glu764) Accession # P35968-1 </div> <div style="background-color: #76b82a; color: white; padding: 5px; text-align: center;"> hFc </div> </div> <div style="display: flex; justify-content: space-around; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Immobilized VEGF R2/KDR hFc Chimera, Human (Cat.No.: Z03965) at 0.5 µg/ml (100µl/Well) on the plate can bind Biotinylated Anti-VEGF R2 Antibody, hFc Tag
Expression System	HEK293
Theoretical Molecular Weight	109.21 kDa
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 150-180 kDa based on Bis-Tris PAGE result.
Formulation	Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O more than 100 µg/ml.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.


Examples




Immobilized Human VEGF165, His Tag at 1 $\mu\text{g/ml}$ (100 $\mu\text{l/well}$) on the plate. Dose response curve for VEGF R2/KDR hFc Chimera, Human with the EC50 of 7.8 ng/ml determined by ELISA.



Immobilized VEGF R2/KDR hFc Chimera, Human, hFc Tag at 0.5 $\mu\text{g/ml}$ (100 $\mu\text{l/well}$) on the plate. Dose response curve for Biotinylated Anti-VEGF R2 Antibody, hFc Tag with the EC50 of 9.7 ng/ml determined by ELISA.



The purity of VEGF R2/KDR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.



VEGF R2/KDR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Background

Target Background : Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.

Synonyms : CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China